Categories
Pharmacology

I will have multiple parts to this assignment.

I have to revise and resubmit an assignment that was previously turned in on creating a clinical program based on my professor’s feedback.
Attached are the instructions to the multi-part assignment and I am focused on resubmitting step 1 (I will open separate orders for steps 2 & 3 later).
I’ve added the professor’s feedback in the comments section of the attached ‘Creating a Clinical Program_prof response.doc’
There is a lot of feedback from the professor, and I think it’s important that you review it all, and we chat about your approach, so please email me with any questions or your thoughts as to the direction. The original plan was to go with the Hypertension program but after the feedback, not sure if we need to change gears and choose something else. She mentioned that if something is already at a 90% adherence rate will the employer really care about that program (maybe but we would need to explain why)? I’ll let you decide based on your review of the feedback.
Below are the links to all the referenced articles around this that the professor wants to ensure are taken into consideration, and I’ve attached those articles without links. It is important that we understand and incorporate the guidance from “The 3 Pillars of value-based decision making” in the attached ‘Clinical programs and value-based decision-making.pdf’ article.
The professor wants this program to be created to be from the perspective of the Magellan PBM, meaning we do not have diagnosis info, we only have drug utilization, adherence, and cost info. As the PBM we need to ensure we are referring to the Magellan formulary for drugs or drug classes that are selected so we know what they already have on the formulary, those preferences, Prior Auth’s etc (more of that info in the “Creating a Clinical Program_prof” document comment sections).

• Magellan Formulary: https://magellan.adaptiverx.com/webSearch/index?key=cnhmbGV4LnBsYW4uUGxhblBkZlR5cGUtNTg
When defining the program criteria, goals, and ROIs…Nothing can be vague..we need specific (SMART) criteria or goals and they need to be based on the data provided In the course with GatorCare Data or Adherence documentation (there will be some assumptions but the majority needs to be focused on the data we have). What is the baseline and what is our target metric.
Here are the online articles that should also be considered
• Disease Management: https://www.amcp.org/about/managed-care-pharmacy-101/concepts-managed-care-pharmacy/disease-management
• Payor Care Management: https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/the-untapped-potential-of-payer-care-management
Keep in mind what is resubmitted is just a summary publish, but it will be the basis for steps 2 & 3 (separate orders), which will require a lot more detail.
——–Previous Instructions——-(see attached revised assignment document)
I will have multiple parts to this assignment. Each Part will build on the previous, so this theme will be carried over to the next assignment. Whatever you select as the topic will be carried over to the next assignment. I’ll give you the full scope of what we will end up doing, but this assignment will be focused on Step 1, which is just a proposal for future work. We have to progressively create a clinical program (we should not use an existing one out there). The goal of the Clinical Program is to improve any data point in either of the 2 attached files (eg. Improve Trends, Mail order, Adherence, etc). Whatever is selected will be the basis of next week’s assignment. Review the ‘Clinical Program Assignment word doc to complete Step 1 and see what the future assignments will be that I will create orders for. Let me know what metric data point you selected to improve.

Categories
Pharmacology

There is a lot of feedback from the professor, and i think it’s important that you review it all, and we chat about your approach, so please email me with any questions or your thoughts as to the direction.

I have to revise and resubmit an assignment that was previously turned in on creating a clinical program based on my professor’s feedback.
Attached are the instructions to the multi-part assignment and I am focused on resubmitting step 1 (I will open separate orders for steps 2 & 3 later).
I’ve added the professor’s feedback in the comments section of the attached ‘Creating a Clinical Program_prof response.doc’
There is a lot of feedback from the professor, and I think it’s important that you review it all, and we chat about your approach, so please email me with any questions or your thoughts as to the direction. The original plan was to go with the Hypertension program but after the feedback, not sure if we need to change gears and choose something else. She mentioned that if something is already at a 90% adherence rate will the employer really care about that program (maybe but we would need to explain why)? I’ll let you decide based on your review of the feedback.
Below are the links to all the referenced articles around this that the professor wants to ensure are taken into consideration, and I’ve attached those articles without links. It is important that we understand and incorporate the guidance from “The 3 Pillars of value-based decision making” in the attached ‘Clinical programs and value-based decision-making.pdf’ article.
The professor wants this program to be created to be from the perspective of the Magellan PBM, meaning we do not have diagnosis info, we only have drug utilization, adherence, and cost info. As the PBM we need to ensure we are referring to the Magellan formulary for drugs or drug classes that are selected so we know what they already have on the formulary, those preferences, Prior Auth’s etc (more of that info in the “Creating a Clinical Program_prof” document comment sections).

• Magellan Formulary: https://magellan.adaptiverx.com/webSearch/index?key=cnhmbGV4LnBsYW4uUGxhblBkZlR5cGUtNTg
When defining the program criteria, goals, and ROIs…Nothing can be vague..we need specific (SMART) criteria or goals and they need to be based on the data provided In the course with GatorCare Data or Adherence documentation (there will be some assumptions but the majority needs to be focused on the data we have). What is the baseline and what is our target metric.
Here are the online articles that should also be considered
• Disease Management: https://www.amcp.org/about/managed-care-pharmacy-101/concepts-managed-care-pharmacy/disease-management
• Payor Care Management: https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/the-untapped-potential-of-payer-care-management
Keep in mind what is resubmitted is just a summary publish, but it will be the basis for steps 2 & 3 (separate orders), which will require a lot more detail.
——–Previous Instructions——-(see attached revised assignment document)
I will have multiple parts to this assignment. Each Part will build on the previous, so this theme will be carried over to the next assignment. Whatever you select as the topic will be carried over to the next assignment. I’ll give you the full scope of what we will end up doing, but this assignment will be focused on Step 1, which is just a proposal for future work. We have to progressively create a clinical program (we should not use an existing one out there). The goal of the Clinical Program is to improve any data point in either of the 2 attached files (eg. Improve Trends, Mail order, Adherence, etc). Whatever is selected will be the basis of next week’s assignment. Review the ‘Clinical Program Assignment word doc to complete Step 1 and see what the future assignments will be that I will create orders for. Let me know what metric data point you selected to improve.

Categories
Pharmacology

-shareable devices

This is a part of main content of E cigarettes’ & vaping in adolescents research, This a group writing so , my portion is to write about:
how did the pandemic/COVID-19 effect teen vaping?
-access to devices
-shareable devices
I have attached our group writing outline and my portion the one in green color, this just to have an idea what I am talking about and also I have attached 3 resources. these resources are on the outline, you can take a look. for you to get the info, please make sure to side them and please don’t just copy direct form the article sorry because someone did it for me before. Thank you

Categories
Pharmacology

Like all other FDA-approved medications, those listed in Table 4.4 demonstrate “well-supported” experimental evidence of safety and effectiveness for improving outcomes for individuals with alcohol and opioid use disorders.

Five medications, approved by the FDA, have been developed to treat alcohol and opioid use disorders. Currently, no approved medications are available to treat marijuana, amphetamine, or cocaine use disorders. Table 4.4. lists these medications. Like all other FDA-approved medications, those listed in Table 4.4 demonstrate “well-supported” experimental evidence of safety and effectiveness for improving outcomes for individuals with alcohol and opioid use disorders. At the same time, all of these medications have side effects; two (methadone and buprenorphine) have the potential to be misused, and methadone (and to a lesser extent buprenorphine) has the potential for overdose. For these reasons, only appropriately trained health care professionals should decide whether medication is needed as part of treatment, how the medication is provided in the context of other clinical services, and under what conditions the medication should be withdrawn or terminated. The combination of behavioral interventions and medications to treat substance use disorders is commonly referred to as MAT. Smith (2015) indicates that MAT is a highly effective treatment option for individuals with alcohol and opioid use disorders. Studies have repeatedly demonstrated the efficacy of MAT at reducing illicit drug use and overdose deaths, improving retention in treatment, and reducing HIV transmission. Some medications used to treat opioid use disorders can be used to manage withdrawal and as maintenance treatment to reduce craving, lessen withdrawal symptoms, and maintain recovery. These medications are used to help a patient function comfortably without illicit opioids or alcohol while balance is gradually restored to the brain circuits that have been altered by prolonged substance use.
A question frequently asked non-medically trained mental health providers is, “does this mean most of these treatments just substitute one opiate for another?” Citing at least one research article, please address the following in your response to this question:
How strong is the body of evidence behind Medication Assisted Treatment?
Does psychotherapy really need to be incorporated in order for MAT to work effectively?
What are the gaps in research?
Table 4.4, Pharmacotherapies Used to Treat Alcohol and Opioid Use Disorders – Facing Addiction in America – NCBI Bookshelf.pdf

Categories
Pharmacology

Reflect on your journey to pharmacy school by answering the following prompts. D

Reflect on your journey to pharmacy school by answering the following prompts.
Describe your journey of getting admitted into pharmacy school
­What happened? How did you feel throughout the process? What went well, what didn’t go well?
­What does it mean now that you are in pharmacy school?
­If you had to go through the application process again, what would you have done differently?
­Is the program what you expected? Why?
­Now that you are here, what are your next steps?
­How has the experience changed the way you think or act? How can you use this experience to further your education or professional development?

Categories
Pharmacology

Identify the biochemical pathway that is altered by the deficiency and the assoc

Identify the biochemical pathway that is altered by the deficiency and the associated disease. Identify a pharmacological treatment strategy that can be used to correct the pathway and treat the disease. must include the biochemical pathway, the name of the resulting disease, the chosen treatment, and the major dose-limiting toxicity (Adverse Event).

Categories
Pharmacology

Hello, I need help to rephrase, correct grammar mistakes, repetition and improve

Hello,
I need help to rephrase, correct grammar mistakes, repetition and improve sentence structure in 11 spots in the paper, The reviewer comments are in the track please follow it.
Please highlight the changes
Thank you

Categories
Pharmacology

Hello, I need help to rephrase, correct grammar mistakes, repetition and improve

Hello,
I need help to rephrase, correct grammar mistakes, repetition and improve sentence structure in 11 spots in the paper, The reviewer comments are in the track please follow it.
Please highlight the changes
Thank you

Categories
Pharmacology

please make ppp of the attached article and focus on the results of increase and

please make ppp of the attached article and focus on the results of increase and decrease proteins in amygdala and piriform cortex with the methods

Categories
Pharmacology

Dear writer, I have a reviewer comment on this manuscriipt, the comment is “Sim

Dear writer,
I have a reviewer comment on this manuscriipt, the comment is “Similar articles are published. only students differ. No novelty of the study ”
I would like to distinguish my study from the similarly published papers.
Just give a paragraph of about 60 words to substantiate that my paper is unique than other published paper in the introdcution and in the abstract. (Please highlight your edit).
Please do this work with highest specialist writer, because this work needs study of the published papers and understanding of this work findings- you can use the following paper to compare and find the substantiate:
1. https://journals.physiology.org/doi/full/10.1152/advan.00005.2019
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907021/
3. https://sci-hub.hkvisa.net/10.1177/026119291204000207